Imidazolyl ethanamide pentandioic acid is under clinical development by Valenta Pharm and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Imidazolyl ethanamide pentandioic acid’s likelihood of approval (LoA) and phase transition for Chemotherapy Induced Neutropenia took place on 27 Jun 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Imidazolyl ethanamide pentandioic acid Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Imidazolyl ethanamide pentandioic acid overview

Imidazolidinyl pentanedioic acid (Ingavirin) is a anti-viral agent. It is formulated as capsules for oral route of administration. Ingavirin is indicated for the treatment and prevention of influenza A, B and other acute viral respiratory infections in adults.

Myelo-001 is under development for the treatment of coronavirus disease 2019 (COVID-19), chemotherapy-induced neutropenia (CIN), chemotherapy-induced myelosuppression(CIM), radiation-induced myelosuppression (RIM) and acute radiation syndrome (ARS). It was also under development for hepatitis C, enterovirus infections, yellow fever and viral respiratory tract infection for pediatric patients under age group of 6 months to 2 years. The drug candidate is administered orally. It is imidazolyl ethanamide pentandioic acid which acts on hematogenesis. It was also under development for chemotherapy-induced thrombocytopenia (CIT).

Valenta Pharm overview

Valenta Pharm (Valenta) is a pharmaceutical company that manufactures and develops innovative medicines. It produces high-quality prescription and over the counter medicines. The company’s products portfolio includes phenazepam, teraligen, aminazin, hypoxen, pantocalcin, nooprin and polition for CNS; ingavirin, immucil, tigroviy and grammidin for cough and cold; trimedat, antareit, exportal and orliks for gastroenterology; and 9 mesyatsev, zydena and bio-max for women and men health. Its other products comprsie of antibacterial products like dioxidin, zitrolid, floracyd; zoreks for hangover treatment; krokha baby cosmetics and Rumycoz for mycology. The company develops medicines for therapeutic areas including immunology, virology and antibacterial therapy, psychoneurology, gastroenterology and urology. It operates in Belarus, Kyrgyzstan, Azerbaijan, Armenia, and Uzbekistan. Valenta is headquartered in Moscow, Russia.

Quick View Imidazolyl ethanamide pentandioic acid LOA Data

Report Segments
  • Innovator (Non-NME)
Drug Name
  • Imidazolyl ethanamide pentandioic acid
Administration Pathway
  • Oral
Therapeutic Areas
  • Ear Nose Throat Disorders
  • Hematological Disorders
  • Infectious Disease
  • Respiratory
  • Toxicology
Key Developers
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.